$1.09
-0.02 (-1.80%)
Open$1.09
Previous Close$1.11
Day High$1.12
Day Low$1.05
52W High$4.98
52W Low$0.78
Volume—
Avg Volume4.20M
Market Cap138.64M
P/E Ratio—
EPS$-1.12
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+1,695.4% upside
Current
$1.09
$1.09
Target
$19.57
$19.57
$11.03
$19.57 avg
$23.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 84.54M | 115.96M | 66.42M |
| Net Income | -148,197,815 | -182,935,171 | 9.87M |
| Profit Margin | -175.3% | -166.5% | 14.9% |
| EBITDA | -125,513,937 | -163,541,681 | 12.50M |
| Free Cash Flow | — | — | 3.90M |
| Rev Growth | -27.1% | -27.1% | +3.3% |
| Debt/Equity | 3.72 | 3.72 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |